Latest News and Press Releases

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy ...

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.

Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its...

STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger...

STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate...

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.